Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
<Research>Citi: CHINA LIFE (02628.HK) Delivers Brilliant 1-3Q Results w/ Accelerated Growth in NBV
Recommend 17 Positive 17 Negative 14 |
||||
|
||||
|
CHINA LIFE (02628.HK) demonstrated remarkable performance in its latest results, with 1-3Q25 NBV surging by 42% YoY on a comparable caliber, accelerating notably from the 20% growth in 1H25, Citi Research issued a research report saying. During the period, first-year premium income grew by 10% to RMB218 billion, as 3Q25 first-year premium growth accelerated noticeably to 52% YoY, far exceeding the mere 1% growth in 1H25. Therefore, the broker rated CHINA LIFE's H-shares at Buy, with a target price of $27.7. AASTOCKS Financial News Website: www.aastocks.com |
||||
Copied to Clipboard
 |
||||
